Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR1459 in AQP4-IgG positive NMOSD
CTR20202415Phase 2Completed
- Sponsor
- Reistone Biopharma
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of edralbrutinib in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Reistone Biopharma. Started Dec 2020; status: completed.
02
Drugs
edralbrutinib
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on CTR20202415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202415.